Medicofarma Biotech (WAR:MDB) Interest Expense: zł-0.62 Mil (TTM As of Mar. 2026)


WAR:MDB Medicofarma Biotech SA WAR:MDB
33 GF Score
Price zł0.44
GF Value zł0.05
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Medicofarma Biotech Interest Expense?

Medicofarma Biotech WAR:MDB 33 Interest Expense is zł-0.62 Mil as of Mar. 2026. GuruFocus rates WAR:MDB with a GF Score™ of 33/100 and a GF Value™ of zł0.05 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Medicofarma Biotech's interest expense for the three months ended in Mar. 2026 was zł -0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was zł-0.62 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Medicofarma Biotech's Operating Income for the three months ended in Mar. 2026 was zł -0.57 Mil. Medicofarma Biotech's Interest Expense for the three months ended in Mar. 2026 was zł -0.00 Mil. Medicofarma Biotech did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Medicofarma Biotech  (WAR:MDB) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Medicofarma Biotech's Interest Expense for the three months ended in Mar. 2026 was zł-0.00 Mil. Its Operating Income for the three months ended in Mar. 2026 was zł-0.57 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was zł0.00 Mil.

Medicofarma Biotech's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Medicofarma Biotech did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Medicofarma Biotech Interest Expense Historical Data

* Premium members only.

The historical data trend for Medicofarma Biotech's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medicofarma Biotech Interest Expense Chart

Medicofarma Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.01 -0.01 -0.17 -0.24 -0.62

Medicofarma Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.00 0.00 -0.62 -0.00
WAR:MDB
33GF Score
Medicofarma Biotech SA WAR:MDB
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medicofarma Biotech Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-0.62 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of zł-0.62 Mil mean?
Medicofarma Biotech (WAR:MDB) has a Interest Expense of zł-0.62 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Medicofarma Biotech and its competitors.
Is Medicofarma Biotech's Interest Expense too high?
Medicofarma Biotech's current Interest Expense is zł-0.62 Mil. Overall, Medicofarma Biotech has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medicofarma Biotech's Interest Expense compare to ZTS and UTHR?
Medicofarma Biotech's Interest Expense of zł-0.62 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Medicofarma Biotech and its competitors. Medicofarma Biotech's current Interest Expense is zł-0.62 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicofarma Biotech stock overvalued right now?
Based on GuruFocus' analysis, Medicofarma Biotech (WAR:MDB) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.05, compared to a current price of zł0.44 — trading 784% above its estimated fair value. The current Interest Expense is zł-0.62 Mil. Medicofarma Biotech's overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Medicofarma Biotech (WAR:MDB), the current Interest Expense is zł-0.62 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medicofarma Biotech (WAR:MDB) Overvalued in 2026?

Based on GuruFocus' analysis, Medicofarma Biotech stock appears to be overvalued. The current stock price of zł0.44 is trading 784% above its estimated GF Value™ of zł0.05. GuruFocus considers Medicofarma Biotech to be Significantly Overvalued.

Key valuation signals for WAR:MDB:

  • Interest Expense: zł-0.62 Mil
  • GF Value™: zł0.05 vs. price of zł0.44 (784% above fair value)
  • GF Score™: 33/100 with 6 warning signs

No single metric tells the full story. See the WAR:MDB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medicofarma Biotech Business Description

Address ul. Sokołowska 9 lok. U19, Warsaw, POL, 01-142
Medicofarma Biotech SA operates in the pharmaceutical industry. The company specializes in contract manufacturing of medical devices, medicinal products and dietary supplements. The business is spread across Austria, Czech Republic, Spain, Ireland, Canada, Germany, Norway, Sweden, Great Britain, and Italy.
33GF Score

Get the complete analysis for WAR:MDB

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł0.44
Price
zł0.05
GF Value